Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer. The company is headquartered in Los Angeles, California and currently employs 96 full-time employees. The company went IPO on 2007-06-05. The firm is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The firm's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The firm is engaged in selling ResponseDX diagnostic testing products. The firm provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.
Follow-Up Questions
Response Genetics Inc (RGDXQ) の株価収益率はいくらですか？
Response Genetics Inc の株価収益率は 0 です。
Response Genetics Inc のCEOは誰ですか？
Mr. Thomas Bologna は Response Genetics Inc の Chairman of the Board で、2011 から在籍しています。
RGDXQ の株価パフォーマンスは？
RGDXQ の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Response Genetics Inc の主な事業テーマや業界は？
Response Genetics Inc は Life Sciences Tools & Services 業界、セクターは Health Care に属しています。
